Abstract
Objective:To investigate the efficacy and safety of LOP(asparaginase + vincristine + dexamethasone) chemotherapy combined with radiotherapy in patients with nasal NK/T cell lymphoma. Method:Sixty patients with nasal NK/T cell lymphoma admitted to our hospital from February 2012 to February 2016 were selected as the study subject. They were randomly divided into group A and group B, 30 cases in each group. All patients were treated with combined chemotherapy and IMRT(intensity modulated conformal radiotherapy). The LOP regimen was used in group A and the CHOP(cyclophosphamide + pirarubicin + vincristine + dexamethasone) regimen was used in group B. The short-term efficacy, long-term efficacy and adverse reactions of the two groups were compared. Result:The clinical manifestations of 60 patients mainly included nasal obstruction(81.67%), accompanied by fever, headache, nosebleed and runny nose. Forty-one patients(68.33%) had only one site of lesion, and 21 patients(35.00%) had multiple sites of lesions. In terms of total remission rate, it was significantly higher in group A than that in group B(93.33% vs. 66.67%, P<0.05). In terms of adverse reactions, the incidence of bone marrow suppression, gastrointestinal reaction and low-protein reaction was significantly lower in group A than that in group B(P<0.05). Three patients died in group A and 11 patients died in group B during the 3-year follow-up. The 3-year survival rate of group A was higher than that of group B(P<0.05). Conclusion:Compared with CHOP+IMRT regimen, the LOP+IMRT regimen for nasal NK/T-cell lymphoma patients resulted in higher overall remission rate, survival rate and lower adverse reactions, so it is worth in clinical promotion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.